What is mosapride citrate used for?

Mosapride citrate, a 5-HT4 receptor agonist, is a prokinetic drug used in functional gastrointestinal disorder including gastroesophageal reflux disease and functional dyspepsia and is safe for it does not cause QT prolongation.

What is a citrate molecule?

Citrate(3-) is a tricarboxylic acid trianion, obtained by deprotonation of the three carboxy groups of citric acid. It has a role as a fundamental metabolite. It is a citrate anion and a tricarboxylic acid trianion.

How do you take mosapride citrate?

For the treatment of heartburn, nausea/vomiting associated with chronic gastritis: In general, for adults, take 1 tablet (5 mg of mosapride citrate), 3 times a day, before or after meal. Strictly follow the instructions.

Is mosapride Prokinetic?

Background: Mosapride is a novel prokinetic agent facilitating acetylcholine release from the enteric cholinergic neurones through a selective 5-HT4 receptor agonistic action. It is also active through its main metabolite M1, which is a 5-HT3 antagonist.

Is mosapride a laxative?

Conclusions: Administration of mosapride increased bowel frequency and ameliorated symptoms of reflux and constipation possibly stimulating the lower intestine. Given that mosapride has those beneficial aspects, it may be a useful prokinetic agent in treating diabetic patients with constipation.

What is the molecular weight of sodium citrate?

258.06 g/molTrisodium citrate / Molar mass

How is citrate metabolized?

Citrate is metabolized by the Krebs cycle (citric acid cycle), mainly in the liver, but also in muscles and kidneys.

Is mosapride a prescription?

Take Mosapride exactly as prescribed by the doctor.

What class of drug is mosapride?

Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Is mosapride antiemetic?

These findings highlight the promising potential of mosapride as an anti-emetic agent.

Can mosapride cause diarrhea?

Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients.